Toronto Dominion Bank
SLNO

Toronto Dominion Bank’s Soleno Therapeutics SLNO Stock Holding History

Toronto Dominion Bank’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,400
Closed -$743K – 1960
2025
Q1 		$743K Buy
+10,400
New +$506K ﹤0.01% 1114

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Toronto Dominion Bank's SLNO Position: Q1 2025 in Review

Toronto Dominion Bank sold out of Soleno Therapeutics (SLNO) in Q1 2025, closing a stake of 10,123 shares — an estimated $493K sold.

Toronto Dominion Bank first reported a position in SLNO in Q4 2024 and held it in 1 quarter. The position peaked at $455K in Q4 2024. 217 funds tracked by Wall St. Rank hold SLNO as of Q1 2025.

  • Toronto Dominion Bank reported no remaining Soleno Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 10,123 Soleno Therapeutics shares in Q1 2025, an estimated $493K.
  • Toronto Dominion Bank first reported a position in Soleno Therapeutics in Q4 2024 and held it in 1 quarter.
  • Toronto Dominion Bank's Soleno Therapeutics position peaked at $455K in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2025.

Based on Toronto Dominion Bank's 13F filing for Q1 2025, filed 15 May 2025.